Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
- Status
- COMPLETED
- Phase
- PHASE4
Clinical Trials Related to Tumor Lysis Syndrome
Related studies linked through entity extraction aliases.
Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE3
Elitek (Rasburicase) Immuno-Monitoring Study
- Status
- TERMINATED
- Phase
- N/A
Fasturtec TLS Treatment / Prophylysis
- Status
- COMPLETED
- Phase
- PHASE4
Rasburicase in Patients at Risk for Tumor Lysis Syndrome
- Status
- COMPLETED
- Phase
- PHASE2
Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy
- Status
- COMPLETED
- Phase
- PHASE4
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
- Status
- COMPLETED
- Phase
- PHASE3
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
- Status
- COMPLETED
- Phase
- N/A